These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8035030)

  • 1. Respiratory syncytial virus-specific cell-mediated immune responses after vaccination with a purified fusion protein subunit vaccine.
    Welliver RC; Tristram DA; Batt K; Sun M; Hogerman D; Hildreth S
    J Infect Dis; 1994 Aug; 170(2):425-8. PubMed ID: 8035030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: evaluation of antibody persistence and possible disease enhancement.
    Tristram DA; Welliver RC; Hogerman DA; Hildreth SW; Paradiso P
    Vaccine; 1994 May; 12(6):551-6. PubMed ID: 8036830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis.
    Piedra PA; Grace S; Jewell A; Spinelli S; Bunting D; Hogerman DA; Malinoski F; Hiatt PW
    Pediatr Infect Dis J; 1996 Jan; 15(1):23-31. PubMed ID: 8684872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection.
    Piedra PA; Glezen WP; Kasel JA; Welliver RC; Jewel AM; Rayford Y; Hogerman DA; Hildreth SW; Paradiso PR
    Vaccine; 1995 Aug; 13(12):1095-101. PubMed ID: 7491817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis.
    Piedra PA; Grace S; Jewell A; Spinelli S; Hogerman DA; Malinoski F; Hiatt PW
    Pediatr Infect Dis J; 1998 Mar; 17(3):217-24. PubMed ID: 9535249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with respiratory syncytial virus vaccines.
    Piedra PA
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S94-9. PubMed ID: 12671459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment.
    Power UF; Plotnicky-Gilquin H; Huss T; Robert A; Trudel M; Ståhl S; Uhlén M; Nguyen TN; Binz H
    Virology; 1997 Apr; 230(2):155-66. PubMed ID: 9143271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches.
    Taleb SA; Al Thani AA; Al Ansari K; Yassine HM
    Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):1817-1827. PubMed ID: 29876771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection against respiratory syncytial virus infection by DNA immunization.
    Li X; Sambhara S; Li CX; Ewasyshyn M; Parrington M; Caterini J; James O; Cates G; Du RP; Klein M
    J Exp Med; 1998 Aug; 188(4):681-8. PubMed ID: 9705950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old.
    Paradiso PR; Hildreth SW; Hogerman DA; Speelman DJ; Lewin EB; Oren J; Smith DH
    Pediatr Infect Dis J; 1994 Sep; 13(9):792-8. PubMed ID: 7808848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly.
    Falsey AR; Walsh EE
    Vaccine; 1997 Jul; 15(10):1130-2. PubMed ID: 9269057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
    Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S
    J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced humoral and CD8+ T cell immunity in mice vaccinated by DNA vaccine against human respiratory syncytial virus through targeting the encoded F protein to dendritic cells.
    Hua Y; Jiao YY; Ma Y; Peng XL; Fu YH; Zhang XJ; Zheng YB; Zheng YP; Hong T; He JS
    Int Immunopharmacol; 2017 May; 46():62-69. PubMed ID: 28259002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
    Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM
    J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant.
    Langley JM; Aggarwal N; Toma A; Halperin SA; McNeil SA; Fissette L; Dewé W; Leyssen M; Toussaint JF; Dieussaert I
    J Infect Dis; 2017 Jan; 215(1):24-33. PubMed ID: 27694633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis.
    Piedra PA; Cron SG; Jewell A; Hamblett N; McBride R; Palacio MA; Ginsberg R; Oermann CM; Hiatt PW;
    Vaccine; 2003 Jun; 21(19-20):2448-60. PubMed ID: 12744878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospects for a respiratory syncytial virus vaccine.
    Hall CB
    Science; 1994 Sep; 265(5177):1393-4. PubMed ID: 7915433
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia.
    Groothuis JR; King SJ; Hogerman DA; Paradiso PR; Simoes EA
    J Infect Dis; 1998 Feb; 177(2):467-9. PubMed ID: 9466539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.